{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:47:49Z","timestamp":1791899269692,"version":"4.3.4"},"reference-count":70,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2029625"],"award-info":[{"award-number":["2029625"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2034017"],"award-info":[{"award-number":["2034017"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["febs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The FEBS Journal"],"abstract":"<jats:p>\n                    T\u00a0cells are central mediators of antitumour immunity and are the cellular basis of many successful cancer immunotherapies, including immune checkpoint blockade, T\u2010cell receptor (TCR)\u2010engineered therapies and chimeric antigen receptor (CAR) T\u00a0cells. However, clinical responses remain variable, and many tumours evade or resist T\u2010cell\u2010mediated control. Understanding how T\u00a0cells recognise tumour cells, deliver cytotoxic signals, produce inflammatory cytokines and shape tumour cell fate is therefore essential for improving modern immunotherapies.\n                    <jats:italic>In vitro<\/jats:italic>\n                    tumour T\u2010cell coculture systems provide a powerful experimental framework for dissecting these processes under controlled conditions. They allow investigators to manipulate antigen specificity, HLA\/MHC restriction, tumour genotype, T\u2010cell activation state, cytokine exposure and drug\u2010mediated perturbation in ways that are difficult to achieve\n                    <jats:italic>in vivo<\/jats:italic>\n                    . However, these systems require careful design, because assay outcomes are strongly influenced by tumour model, antigen expression, effector\u2010to\u2010target ratio, assay duration and readout. This guide provides a practical framework for studying tumour T\u2010cell interactions\n                    <jats:italic>in vitro<\/jats:italic>\n                    , with a focus on CD8+ T\u2010cell\u2010mediated tumour recognition and killing. It discusses commonly used mouse and human antigen\u2010specific models, how antigen expression and presentation can be experimentally controlled, T\u2010cell activation and coculture conditions, cytotoxicity assays, immune synapse imaging, competition assays, cytokine\u2010mediated bystander killing, transcriptional profiling, CRISPR perturbation strategies, therapeutic testing and patient\u2010derived models. The aim is to help researchers choose the most appropriate model, experimental setup and readout for the biological question being asked and to avoid common interpretive pitfalls when studying tumour immune sensitivity, resistance and therapeutic response.\n                  <\/jats:p>","DOI":"10.1111\/febs.70765","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:01:26Z","timestamp":1791896486000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A guide to studying tumour\u2010T\u2010cell interactions using\n                    <i>in\u00a0vitro<\/i>\n                    coculture assays"],"prefix":"10.1111","author":[{"given":"Nooshin","family":"Khoshdoozmasouleh","sequence":"first","affiliation":[{"name":"Olivia Newton\u2010John Cancer Research Institute  Melbourne Australia"},{"name":"School of Cancer Medicine La Trobe University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9891-5078","authenticated-orcid":false,"given":"Conor J.","family":"Kearney","sequence":"additional","affiliation":[{"name":"Olivia Newton\u2010John Cancer Research Institute  Melbourne Australia"},{"name":"School of Cancer Medicine La Trobe University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T\u00a0cell basic science to clinical practice","volume":"20","author":"Waldman AD","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11040835","article-title":"T\u00a0cell based immunotherapy for cancer: approaches and strategies","volume":"11","author":"Want MY","year":"2023","journal-title":"Vaccines"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian SL","year":"2015","journal-title":"Cancer Cell"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June CH","year":"2018","journal-title":"N Engl J Med"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR\u2010engineered T\u00a0cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu E","year":"2023","journal-title":"Sci Adv"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2010immune set point","volume":"541","author":"Chen DS","year":"2017","journal-title":"Nature"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/369031a0","article-title":"Cytotoxicity mediated by T\u00a0cells and natural killer cells is greatly impaired in perforin\u2010deficient mice","volume":"369","author":"Kagi D","year":"1994","journal-title":"Nature"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nri911","article-title":"Functional significance of the perforin\/granzyme cell death pathway","volume":"2","author":"Trapani JA","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41418-022-01059-z","article-title":"Harnessing TRAIL\u2010induced cell death for cancer therapy: a long walk with thrilling discoveries","volume":"30","author":"Montinaro A","year":"2023","journal-title":"Cell Death Differ"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.it.2021.10.003","article-title":"Unleashing TNF cytotoxicity to enhance cancer immunotherapy","volume":"42","author":"Freeman AJ","year":"2021","journal-title":"Trends Immunol"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","article-title":"A critical role for Fas\u2010mediated off\u2010target tumor killing in T\u2010cell immunotherapy","volume":"11","author":"Upadhyay R","year":"2021","journal-title":"Cancer Discov"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/cdd.2017.94","article-title":"PD\u2010L1 and IAPs co\u2010operate to protect tumors from cytotoxic lymphocyte\u2010derived TNF","volume":"24","author":"Kearney CJ","year":"2017","journal-title":"Cell Death Differ"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aar3451","article-title":"Tumor immune evasion arises through loss of TNF sensitivity","volume":"3","author":"Kearney CJ","year":"2018","journal-title":"Sci Immunol"},{"key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1002\/cam4.1700","article-title":"Interferon gamma in cancer immunotherapy","volume":"7","author":"Ni L","year":"2018","journal-title":"Cancer Med"},{"key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2014.09.004","article-title":"Mechanism of action of immunotherapy","volume":"41","author":"Disis ML","year":"2014","journal-title":"Semin Oncol"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T\u00a0cell activation","volume":"27","author":"Smith\u2010Garvin JE","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tibs.2017.11.008","article-title":"TCR signaling: mechanisms of initiation and propagation","volume":"43","author":"Courtney AH","year":"2018","journal-title":"Trends Biochem Sci"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas J","year":"2004","journal-title":"J Immunol"},{"key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-018-0020-8","article-title":"Regulatory mechanisms in T\u00a0cell receptor signalling","volume":"18","author":"Gaud G","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma P","year":"2017","journal-title":"Cell"},{"key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade\u2010Feldman M","year":"2017","journal-title":"Nat Commun"},{"key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD\u20101 blockade in melanoma","volume":"375","author":"Zaretsky JM","year":"2016","journal-title":"N Engl J Med"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD\u20101 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin DS","year":"2017","journal-title":"Cancer Discov"},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci JL","year":"2016","journal-title":"Cell"},{"key":"e_1_2_10_26_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01818","article-title":"The TNF paradox in cancer progression and immunotherapy","volume":"10","author":"Montfort A","year":"2019","journal-title":"Front Immunol"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12672-025-02238-3","article-title":"Role of metabolic transformation in cancer immunotherapy resistance: molecular mechanisms and therapeutic implications","volume":"16","author":"Shende S","year":"2025","journal-title":"Discov Oncol"},{"key":"e_1_2_10_28_1","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041143","article-title":"Cancer resistance to immunotherapy: comprehensive insights with future perspectives","volume":"15","author":"Said SS","year":"2023","journal-title":"Pharmaceutics"},{"key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","article-title":"Clinical landscape of macrophage\u2010reprogramming cancer immunotherapies","volume":"131","author":"Rannikko JH","year":"2024","journal-title":"Br J Cancer"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.actbio.2021.03.076","article-title":"Engineered in vitro tumor models for cell\u2010based immunotherapy","volume":"132","author":"Ando Y","year":"2021","journal-title":"Acta Biomater"},{"key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1021\/acsbiomaterials.7b00077","article-title":"In vitro modeling of tumor\u2010immune system interaction","volume":"4","author":"Mengus C","year":"2018","journal-title":"ACS Biomater Sci Eng"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher TN","year":"2015","journal-title":"Science"},{"key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/334395a0","article-title":"T\u2010cell antigen receptor genes and T\u2010cell recognition","volume":"334","author":"Davis MM","year":"1988","journal-title":"Nature"},{"key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan RA","year":"2006","journal-title":"Science"},{"key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.4049\/jimmunol.162.4.2227","article-title":"Isolation of high avidity melanoma\u2010reactive CTL from heterogeneous populations using peptide\u2010MHC tetramers","volume":"162","author":"Yee C","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain M","year":"2013","journal-title":"Cancer Discov"},{"key":"e_1_2_10_37_1","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1002\/(SICI)1521-4141(199812)28:12<4162::AID-IMMU4162>3.0.CO;2-E","article-title":"Delayed kinetics of tumor necrosis factor\u2010mediated bystander lysis by peptide\u2010specific CD8+ cytotoxic T lymphocytes","volume":"28","author":"Smyth MJ","year":"1998","journal-title":"Eur J Immunol"},{"key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/febs.17003","article-title":"Tumor immune evasion: insights from CRISPR screens and future directions","volume":"291","author":"Djajawi TM","year":"2024","journal-title":"FEBS J"},{"key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1046\/j.1440-1711.2000.00889.x","article-title":"Characterization of the ovalbumin\u2010specific TCR transgenic line OT\u2010I: MHC elements for positive and negative selection","volume":"78","author":"Clarke SR","year":"2000","journal-title":"Immunol Cell Biol"},{"key":"e_1_2_10_40_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1084\/jem.20091279","article-title":"CD8+ T\u00a0cell concentration determines their efficiency in killing cognate antigen\u2010expressing syngeneic mammalian cells in vitro and in mouse tissues","volume":"207","author":"Budhu S","year":"2010","journal-title":"J Exp Med"},{"key":"e_1_2_10_41_1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4049\/jimmunol.1302289","article-title":"Inflammation and TCR signal strength determine the breadth of the T\u00a0cell response in a bim\u2010dependent manner","volume":"192","author":"Zehn D","year":"2014","journal-title":"J Immunol"},{"key":"e_1_2_10_42_1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20030590","article-title":"Tumor regression and autoimmunity after reversal of a functionally tolerant state of self\u2010reactive CD8+ T\u00a0cells","volume":"198","author":"Overwijk WW","year":"2003","journal-title":"J Exp Med"},{"key":"e_1_2_10_43_1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/342559a0","article-title":"Tolerance induction in double specific T\u2010cell receptor transgenic mice varies with antigen","volume":"342","author":"Pircher H","year":"1989","journal-title":"Nature"},{"key":"e_1_2_10_44_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.immuni.2009.11.010","article-title":"Prolonged interleukin\u20102Ralpha expression on virus\u2010specific CD8+ T\u00a0cells favors terminal\u2010effector differentiation in vivo","volume":"32","author":"Kalia V","year":"2010","journal-title":"Immunity"},{"key":"e_1_2_10_45_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon\u2010gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro F","year":"2018","journal-title":"Front Immunol"},{"key":"e_1_2_10_46_1","first-page":"1","article-title":"NY\u2010ESO\u20101: review of an immunogenic tumor antigen","volume":"95","author":"Gnjatic S","year":"2006","journal-title":"Adv Cancer Res"},{"key":"e_1_2_10_47_1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY\u2010ESO\u20101","volume":"29","author":"Robbins PF","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_48_1","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/s41467-022-29205-8","article-title":"CRISPR activation screen identifies BCL\u20102 proteins and B3GNT2 as drivers of cancer resistance to T cell\u2010mediated cytotoxicity","volume":"13","author":"Joung J","year":"2022","journal-title":"Nat Commun"},{"key":"e_1_2_10_49_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY\u2010ESO\u20101 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas R","year":"2018","journal-title":"Front Immunol"},{"key":"e_1_2_10_50_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2022.100089","article-title":"MART\u20101 TCR gene\u2010modified peripheral blood T\u00a0cells for the treatment of metastatic melanoma: a phase I\/IIa clinical trial","volume":"15","author":"Rohaan MW","year":"2022","journal-title":"Immunooncol Technol"},{"key":"e_1_2_10_51_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR\u2010engineered T\u00a0cells: current strategies, challenges, and prospects","volume":"13","author":"Shafer P","year":"2022","journal-title":"Front Immunol"},{"key":"e_1_2_10_52_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR\u2010T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti I","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_2_10_53_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/2326-6066.CIR-18-0428","article-title":"Antagonism of IAPs enhances CAR T\u2010cell efficacy","volume":"7","author":"Michie J","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"e_1_2_10_54_1","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T\u00a0cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport AJ","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_2_10_55_1","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal JT","year":"2018","journal-title":"Cell"},{"key":"e_1_2_10_56_1","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor\u2010reactive T\u00a0cells by co\u2010culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra KK","year":"2018","journal-title":"Cell"},{"key":"e_1_2_10_57_1","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1007\/s00262-023-03476-6","article-title":"Using patient\u2010derived tumor organoids from common epithelial cancers to analyze personalized T\u2010cell responses to neoantigens","volume":"72","author":"Parikh AY","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"e_1_2_10_58_1","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/2159-8290.CD-23-1266","article-title":"IL2 targeted to CD8+ T\u00a0cells promotes robust effector T\u2010cell responses and potent antitumor immunity","volume":"14","author":"Moynihan KD","year":"2024","journal-title":"Cancer Discov"},{"key":"e_1_2_10_59_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL\u20107 and IL\u201015 instruct the generation of human memory stem T\u00a0cells from naive precursors","volume":"121","author":"Cieri N","year":"2013","journal-title":"Blood"},{"key":"e_1_2_10_60_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116665","article-title":"A TAK1 cytokine toxicity checkpoint controls anti\u2010cancer immunity","volume":"45","author":"Djajawi TM","year":"2026","journal-title":"Cell Rep"},{"key":"e_1_2_10_61_1","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T\u00a0cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade\u2010Feldman M","year":"2018","journal-title":"Cell"},{"key":"e_1_2_10_62_1","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20188746","article-title":"Current best practices in single\u2010cell RNA\u2010seq analysis: a tutorial","volume":"15","author":"Luecken MD","year":"2019","journal-title":"Mol Syst Biol"},{"key":"e_1_2_10_63_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116738","article-title":"CRISPR screens define unified hallmarks of cancer cell\u2010autonomous immune evasion","volume":"45","author":"Huber A","year":"2026","journal-title":"Cell Rep"},{"key":"e_1_2_10_64_1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2746-2","article-title":"Functional genomic landscape of cancer\u2010intrinsic evasion of killing by T\u00a0cells","volume":"586","author":"Lawson KA","year":"2020","journal-title":"Nature"},{"key":"e_1_2_10_65_1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41590-022-01315-x","article-title":"In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer","volume":"23","author":"Dubrot J","year":"2022","journal-title":"Nat Immunol"},{"key":"e_1_2_10_66_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23270","article-title":"In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso RT","year":"2017","journal-title":"Nature"},{"key":"e_1_2_10_67_1","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb9561","article-title":"Autophagy protects tumors from T cell\u2010mediated cytotoxicity via inhibition of TNFalpha\u2010induced apoptosis","volume":"5","author":"Young TM","year":"2020","journal-title":"Sci Immunol"},{"key":"e_1_2_10_68_1","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-021-00093-4","article-title":"High\u2010content CRISPR screening","volume":"2","author":"Bock C","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"e_1_2_10_69_1","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.4049\/jimmunol.1901396","article-title":"Efficient CRISPR\/Cas9 gene editing in uncultured naive mouse T\u00a0cells for in vivo studies","volume":"204","author":"Nussing S","year":"2020","journal-title":"J Immunol"},{"key":"e_1_2_10_70_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1615\/CritRevImmunol.2015014417","article-title":"The role of the immunological synapse formed\u00a0by cytotoxic lymphocytes in immunodeficiency and anti\u2010tumor immunity","volume":"35","author":"Kearney CJ","year":"2015","journal-title":"Crit Rev Immunol"},{"key":"e_1_2_10_71_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113831","article-title":"PRMT1 acts as a suppressor of MHC\u2010I and anti\u2010tumor immunity","volume":"43","author":"Djajawi TM","year":"2024","journal-title":"Cell Rep"}],"container-title":["The FEBS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/febs.70765","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/febs.70765","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/febs.70765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:01:35Z","timestamp":1791896495000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1111\/febs.70765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":70,"alternative-id":["10.1111\/febs.70765"],"URL":"https:\/\/doi.org\/10.1111\/febs.70765","archive":["Portico"],"relation":{},"ISSN":["1742-464X","1742-4658"],"issn-type":[{"value":"1742-464X","type":"print"},{"value":"1742-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"2026-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"febs.70765"}}